Skip to main content
. 2017 Dec 21;9(2):2646–2659. doi: 10.18632/oncotarget.23522

Figure 1. Expression of RUNX2 and E-cadherin during epithelial differentiation.

Figure 1

(A) The ADSC morphology under the microscope after treatment with induced medium (×200). (B) Protein levels of RUNX2, E-cadherin, CK18 and ZO-1 in ADSCs during epithelial differentiation were determined by western-blot, β-actin was used as loading control. (C) The mRNA expression of RUNX2, E-cadherin, CK18 and ZO-1 were detected by real-time RT-PCR. Relative mRNA expressions are normalized to β-actin. (D) Immunofluorescence analysis to assess the expression of RUNX2, E-cadherin, CK18 and ZO-1 in ADSCs during epithelial differentiation (right panel) in comparison to control cells (left panel) (×100). Nuclei are visualized by 4,6-diamidino-2-phenylindole staining. These data are expressed as the mean ± SD (*P<0.05, **P<0.01). Each experiment was repeated at least three times.